title: Effect of ubenimex on a CD5-CD13+ CLL patient with an aggressive clinical course.
authors.forename: A
authors.initials: A
authors.lastname: Horikoshi
authors.forename: T
authors.initials: T
authors.lastname: Irie
authors.forename: H
authors.initials: H
authors.lastname: Ishizuka
authors.forename: T
authors.initials: T
authors.lastname: Ohkubo
authors.forename: Y
authors.initials: Y
authors.lastname: Hosokawa
authors.forename: S
authors.initials: S
authors.lastname: Sawada
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D018826:CD13 Antigens; D018956:CD5 Antigens; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male
chemical_list: D000903:Antibiotics, Antineoplastic; D018956:CD5 Antigens; D018826:CD13 Antigens; D007930:Leucine; C012211:ubenimex